The Drug Regulatory Authority of Pakistan (DRAP) has banned Famila Injection Batch 083 due to quality concerns.
DRAP issued a Recall Alert, directing pharmacies across Pakistan to immediately stop selling the batch. Pharmacies must return all available stock to Zafa Pharmaceutical Company, based in Karachi. This action follows testing by a Federal Drug Inspector in Karachi. The Central Drugs Laboratory declared the batch substandard.
In response, DRAP ordered Zafa Pharmaceutical to cease the distribution of this batch. The National Regulatory Field Force will enhance market surveillance to ensure compliance with the ban.
Moreover, DRAP advised healthcare providers and patients to avoid using Famila Injection Batch 083. The authority stressed patient safety as a primary concern and urged pharmacies to act swiftly in returning the affected stock.
